• HNSCC
• TCGA
• WGCNA
• cell cycle
• immune infiltration
• survival

• Humans
• Squamous Cell Carcinoma of Head and Neck/genetics
• Squamous Cell Carcinoma of Head and Neck/pathology
• Squamous Cell Carcinoma of Head and Neck/mortality
• Biomarkers, Tumor/genetics
• Biomarkers, Tumor/metabolism
• Prognosis
• Head and Neck Neoplasms/genetics
• Head and Neck Neoplasms/pathology
• Head and Neck Neoplasms/metabolism
• Head and Neck Neoplasms/mortality
• Hyaluronan Receptors/genetics
• Hyaluronan Receptors/metabolism
• Gene Expression Regulation, Neoplastic
• Gene Regulatory Networks
• Gene Expression Profiling
• Survival Analysis
• Cell Cycle Proteins/genetics
• Cell Cycle Proteins/metabolism
• Male
• Extracellular Matrix Proteins

• glycerol-3-phosphate dehydrogenase 1-like
• hepatocellular carcinoma
• metabolic dysregulation
• prognosis
• tumorigenesis

• Humans
• Carcinogenesis
• Carcinoma, Hepatocellular/genetics
• Epithelial-Mesenchymal Transition/genetics
• Liver Neoplasms/genetics
• Prognosis

• MR/V02955X/1 Medical Research Council

• alternative splicing
• ferroptosis
• hepatitis B virus (HBV)
• hepatocellular carcinoma (HCC)
• proliferating cell nuclear antigen clamp-associated factor (PCLAF)
• sorafenib resistance

• Humans
• Carcinoma, Hepatocellular/metabolism
• Cell Line, Tumor
• Ferroptosis
• Hepatitis B
• Hepatitis B virus
• Liver Neoplasms/metabolism
• Serine-Arginine Splicing Factors
• Sorafenib/pharmacology

Gastrointestinal (GI) cancers, including malignancies in the gastrointestinal tract and accessory organs of digestion, represent the leading cause of death worldwide due to the poor prognosis of most GI cancers. An investigation into the potential molecular targets of prediction, diagnosis, prognosis, and therapy in GI cancers is urgently required. Proliferating cell nuclear antigen (PCNA) clamp associated factor (PCLAF), which plays an essential role in cell proliferation, apoptosis, and cell cycle regulation by binding to PCNA, is a potential molecular target of GI cancers as it contributes to a series of malignant properties, including tumorigenesis, epithelial-mesenchymal transition, migration, and invasion. Furthermore, PCLAF is an underlying plasma prediction target in colorectal cancer and liver cancer. In addition to GI cancers, PCLAF is also involved in other types of cancers and autoimmune diseases. Several pivotal pathways, including the Rb/E2F pathway, NF-κB pathway, and p53-p21 cascade, are implicated in PCLAF-mediated diseases. PCLAF also contributes to some diseases through dysregulation of the p53 pathway, WNT signal pathway, MEK/ERK pathway, and PI3K/AKT/mTOR signal cascade. This review mainly describes in detail the role of PCLAF in physiological status and GI cancers. The signaling pathways involved in PCLAF are also summarized. Suppression of the interaction of PCLAF/PCNA or the expression of PCLAF might be potential biological therapeutic strategies for GI cancers.

• Proliferating cell nuclear antigen
• Proliferating cell nuclear antigen clamp associated factor
• Transcript variant
• Gastrointestinal cancers
• Signal pathway
• Biological therapeutic

To explore the prognosis of Galectins (LGALS) expression on patients with ovarian cancer, the prognosis of LGALS members in ovarian cancer was retrieved and analyzed by using 'Kaplan-Meier plotter' database. The relation of LGALS to overall survival (OS) was evaluated according to histological subtypes, clinical stages and pathological grade. Quantitative real-time polymerase chain reaction and western blot were used to detect the mRNA and protein expression of LGALS in ovarian cancer and normal ovarian cells. Immunohistochemistry was applied to evaluate the different expression of LGALS between cancer and normal tissues. In total patients with ovarian cancer, LGALS4, LGALS8, LGALS10 and LGALS13 mRNA levels were related to a better OS, and LGALS1 to a worse OS. LGALS1 predicted a worse OS in women with serous, stages III+IV or grade II ovarian cancer. LGALS4 predicted a better OS in patients with endometrioid, stages I+II or grade III ovarian cancer. LGALS10 predicted a longer OS in females with serous, all stages, or grade III cancer. LGALS8 overexpression was related to a better OS in all stages. Notably, mRNA and protein expressions of LGALS4, LGALS10 and LGALS13 were decreased in cancer cells than those in normal cells (P<0.05). Additionally, the immunostaining score of LGALS8, LGALS10 and LGALS13 expression were lower but LGALS1 was higher in caner tissues than those in normal tissues (P<0.001). In conclusion, LGALS10 possibly is a valuable biomarker for predicting a favorable prognosis in patients with ovarian cancer, especially with serous, all stages and grade III cancer.

• Galectins (LGALS)
• Kaplan-Meier Plotter
• Ovarian cancer
• Prognosis.